The 2022 WHO report updated the classification of G6PD variants based on G6PD activity, with variants having activity below 20% of the adjusted male median classified as “class A” for chronic non-spherocytic hemolytic anemia, below 45% as “class B” for triggered acute hemolytic anemia, between 60 and 150% as “class C” with no hemolysis, and the remaining variants classified as “class U” with uncertain clinical significance [5]. This evidence concerns the gene G6PD and anemia, nonspherocytic hemolytic.